Bayer AGBAYZF +20.72%53 EBITDA Margin % is 35.19% as of Mar. 2026, which is 56% above its 10-year median of 22.53. GuruFocus rates BAYZF with a GF Score™ of 53/100 and a GF Value™ of $31.90 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 955 Drug Manufacturers companies, Bayer AG ranks worse than 64.19% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bayer AG's EBITDA for the
three
months ended in Mar. 2026 was $5,453 Mil. Bayer AG's Revenue for the
three
months ended in Mar. 2026 was $15,497 Mil. Therefore, Bayer AG's EBITDA margin for the quarter that ended in Mar. 2026 was 35.19%.
Bayer AG (OTCPK:BAYZF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bayer AG EBITDA Margin % Related Terms
Bayer AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bayer AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BAYZF vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Bayer AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayer AG EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bayer AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bayer AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bayer AG (BAYZF) has a EBITDA Margin % of 35.19% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bayer AG and its competitors. This is 56% above median its historical median of 22.53. According to the industry distribution chart, Bayer AG ranks #613 out of 955 companies in the Drug Manufacturers industry, placing it in the top 64.2%.
Is Bayer AG's EBITDA Margin % too high?
Bayer AG's current EBITDA Margin % of 35.19% is 56% above median its 10-year median of 22.53. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Bayer AG's value of 35.19% is 184% above this industry median. Based on the distribution chart, Bayer AG ranks #613 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bayer AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #613 out of 955 companies for EBITDA Margin %. This places Bayer AG in the lower half of its industry. The industry median EBITDA Margin % is 12.39. Bayer AG's value of 35.19% is 184% above this benchmark. While the company's 10-year median is 22.53 vs. the industry median of 12.39, Bayer AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bayer AG's current EBITDA Margin % of 35.19% is 184% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bayer AG and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bayer AG's current EBITDA Margin % is 35.19%, which is 56% above median its own 10-year median of 22.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (BAYZF) is currently considered Significantly Overvalued. The stock's GF Value™ is $31.90, compared to a current price of $53.20 — trading 66.8% above its estimated fair value. The current EBITDA Margin % is 35.19%, which is 56% above median its 10-year median of 22.53 and 184% above the Drug Manufacturers industry median of 12.39. Bayer AG's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bayer AG (BAYZF), the current EBITDA Margin % is 35.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (BAYZF) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of $53.20 is trading 66.8% above its estimated GF Value™ of $31.90.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for BAYZF:
EBITDA Margin %: 35.19% (56% above median its 10-year median of 22.53)
GF Value™: $31.90 vs. price of $53.20 (66.8% above fair value)
Industry Position: 184% above the Drug Manufacturers median (#613 of 955)
No single metric tells the full story. See the BAYZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
53GF Score
Get the complete analysis for BAYZF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BAYZF has been successfully added to your 
